Company intelligence / Profile preview

Aurora Therapeutics

Zurich, Zurich, Switzerland

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Aurora Therapeutics is developing a lead CAR-T cell therapy targeting B7-H3 (CD276) for the treatment of pediatric solid tumors, particularly neuroblastoma. Preclinical studies have shown significant anti-tumor activity and a favorable safety profile using their proprietary CAR construct. The company is currently advancing this program toward Phase 1 clinical trials.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

University Children's Hospital ZurichUniversity of Basel

Beyond the preview

Go deeper on Aurora Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurora Therapeutics.

Explore the full profile